Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

completed267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_3

Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer

NCT02114359
completedphase_2

Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE

NCT01187212
terminatedphase_2

A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer

NCT01967875

Clinical Trials (3)

Showing 3 of 3 trials
NCT02114359Phase 3

Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer

Completed
NCT01187212Phase 2

Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE

Completed
NCT01967875Phase 2

A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3